Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KALV
KALV logo

KALV News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

KALV News

Investor Rights Law Firm Investigates RE/MAX and Others

2d agoPRnewswire

KALVISTA PHARMACEUTICALS INC: STIFEL Downgrades to Hold from Buy and Lowers Target Price to $27 from $42

2d agomoomoo

Investor Rights Law Firm Investigates Multiple Companies

6d agoPRnewswire

KALVISTA PHARMACEUTICALS INC: LEERINK PARTNERS LOWERS RATING TO MARKET PERFORM FROM OUTPERFORM; INCREASES TARGET PRICE TO $27 FROM $22

Apr 30 2026moomoo

KalVista Pharmaceuticals Acquired by Italy's Chiesi Group

Apr 29 2026Fool

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

Apr 29 2026PRnewswire

Investigation into KalVista's Transaction with Chiesi Group

Apr 29 2026PRnewswire

Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion

Apr 29 2026Newsfilter

KALV Events

05/07 16:50
Stifel Downgrades KalVista to Hold After $27 Acquisition by Chiesi Group
Stifel analyst Paul Matteis downgraded KalVista to Hold from Buy after the company entered into a merger agreement to be acquired by Chiesi Group at a price of $27 per share in cash.
05/01 06:10
H.C. Wainwright Downgrades KalVista to Neutral, Price Target Cut to $27
H.C. Wainwright analyst Andrew Fein downgraded KalVista to Neutral from Buy with a price target of $27, down from $37, after the company entered into a merger agreement to be acquired by Chiesi Group at a price of $27 per share in cash at closing. The firm does not expect an additional bidder to emerge.
04/30 13:00
Needham Downgrades KalVista to Hold After $27 Acquisition Announcement
Needham downgraded KalVista to Hold from Buy after Chiesi announced an agreement to acquire KalVista for $27 per share in cash.

KALV Monitor News

Kalvista Pharmaceuticals reaches 52-week high amid market gains

Apr 29 2026

KALV Earnings Analysis

No Data

No Data

People Also Watch